GlassScriptPhysician profile
Odel Ruano
NPI 1659384147
$6,261.57
in general payments reported to CMS, 2019-2025
53 companies · $661 in 2025
The $661 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $309 · 2021: $1,265 · 2022: $1,078 · 2023: $891 · 2024: $860 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.44 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $495.10 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $473.32 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $409.19 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $395.25 | 2021-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $363.58 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $338.94 | 2019-2024 | Veozah |
| Amgen INC. | $332.44 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $269.52 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.17 | 2019-2022 | |
| Novo Nordisk INC | $265.97 | 2021-2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $214.55 | 2021-2022 | |
| Insmed, INC. | $195.40 | 2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $173.26 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $149.99 | 2021-2022 | |
| Exact Sciences Corporation | $141.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odel Ruano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.